These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 18419745)

  • 1. A new VKORC1 allelic variant (p.Trp59Arg) in a patient with partial resistance to acenocoumarol and phenprocoumon.
    Wilms EB; Touw DJ; Conemans JM; Veldkamp R; Hermans M
    J Thromb Haemost; 2008 Jul; 6(7):1224-6. PubMed ID: 18419745
    [No Abstract]   [Full Text] [Related]  

  • 2. [Partial resistance to acenocoumarol and phenprocoumon caused by enzyme polymorphism].
    Wilms EB; Veldkamp RF; van Meegen E; Touw DJ
    Ned Tijdschr Geneeskd; 2006 Sep; 150(38):2095-8. PubMed ID: 17036862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Partial resistance to acenocoumarol and phenprocoumon caused by enzyme polymorphism].
    Niermeijer MF
    Ned Tijdschr Geneeskd; 2006 Dec; 150(51):2839; author reply 2839-40. PubMed ID: 17216734
    [No Abstract]   [Full Text] [Related]  

  • 4. [Resistance to coumarin derivatives due to mutated vitamin-K enzyme].
    Hermans MH; Poodt J; van Geest-Daalderop JH; Péquériaux NC; Conemans JM
    Ned Tijdschr Geneeskd; 2009; 153():A691. PubMed ID: 19857286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol.
    van Schie RM; Babajeff AM; Schalekamp T; Wessels JA; le Cessie S; de Boer A; van der Meer FJ; van Meegen E; Verhoef TI; Rosendaal FR; Maitland-van der Zee AH;
    J Thromb Haemost; 2012 May; 10(5):767-72. PubMed ID: 22409277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Resistance to acenocoumarol revealing a missense mutation of the vitamin K epoxyde reductase VKORC1: a case report].
    Mboup MC; Dia K; Ba DM; Fall PD
    Ann Cardiol Angeiol (Paris); 2015 Feb; 64(1):59-61. PubMed ID: 24095214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VKORC1 mutations in patients with partial resistance to phenprocoumon.
    Schmeits PC; Hermans MH; van Geest-Daalderop JH; Poodt J; de Sauvage Nolting PR; Conemans JM
    Br J Haematol; 2010 Mar; 148(6):955-7. PubMed ID: 19961479
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
    Beinema M; Brouwers JR; Schalekamp T; Wilffert B
    Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes.
    Teichert M; Eijgelsheim M; Uitterlinden AG; Buhre PN; Hofman A; De Smet PA; Visser LE; Stricker BH
    Pharmacogenet Genomics; 2011 Jan; 21(1):26-34. PubMed ID: 21063236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk.
    Reitsma PH; van der Heijden JF; Groot AP; Rosendaal FR; Büller HR
    PLoS Med; 2005 Oct; 2(10):e312. PubMed ID: 16201835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users.
    Verhoef TI; Redekop WK; Hegazy H; de Boer A; Maitland-van der Zee AH;
    J Thromb Haemost; 2012 Dec; 10(12):2610-2. PubMed ID: 23016521
    [No Abstract]   [Full Text] [Related]  

  • 12. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements.
    Cadamuro J; Dieplinger B; Felder T; Kedenko I; Mueller T; Haltmayer M; Patsch W; Oberkofler H
    Eur J Clin Pharmacol; 2010 Mar; 66(3):253-60. PubMed ID: 20020283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period.
    Teichert M; van Schaik RH; Hofman A; Uitterlinden AG; de Smet PA; Stricker BH; Visser LE
    Clin Pharmacol Ther; 2009 Apr; 85(4):379-86. PubMed ID: 19225451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A vitamin K epoxide reductase-oxidase complex gene polymorphism (-1639G>A) and interindividual variability in the dose-effect of vitamin K antagonists.
    Stepien E; Branicka A; Ciesla-Dul M; Undas A
    J Appl Genet; 2009; 50(4):399-403. PubMed ID: 19875892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement.
    Schalekamp T; Brassé BP; Roijers JF; van Meegen E; van der Meer FJ; van Wijk EM; Egberts AC; de Boer A
    Clin Pharmacol Ther; 2007 Feb; 81(2):185-93. PubMed ID: 17192772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of oral anticoagulants: a basis for dose individualization.
    Stehle S; Kirchheiner J; Lazar A; Fuhr U
    Clin Pharmacokinet; 2008; 47(9):565-94. PubMed ID: 18698879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement.
    Puehringer H; Loreth RM; Klose G; Schreyer B; Krugluger W; Schneider B; Oberkanins C
    Eur J Clin Pharmacol; 2010 Jun; 66(6):591-8. PubMed ID: 20376629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.
    Bodin L; Verstuyft C; Tregouet DA; Robert A; Dubert L; Funck-Brentano C; Jaillon P; Beaune P; Laurent-Puig P; Becquemont L; Loriot MA
    Blood; 2005 Jul; 106(1):135-40. PubMed ID: 15790782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals.
    Aklillu E; Leong C; Loebstein R; Halkin H; Gak E
    Blood; 2008 Apr; 111(7):3903-4. PubMed ID: 18362220
    [No Abstract]   [Full Text] [Related]  

  • 20. [Vitamin K epoxide reductase: Fresh blood for oral anticoagulant therapies].
    Loriot MA; Beaune P
    Rev Med Interne; 2006 Dec; 27(12):979-82. PubMed ID: 17070618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.